Levenue 250 Tablet is an anti-epileptic medicine used to prevent and control seizures in epilepsy. It can be used alone or with other medications and works by suppressing abnormal electrical activity in the brain, helping you manage seizures effectively.
Benefits
- 
Helps prevent various types of seizures, including myoclonic, partial-onset, and generalized tonic-clonic seizures 
- 
Reduces symptoms like uncontrolled jerking movements, confusion, loss of awareness, and anxiety 
- 
Can improve safety for daily activities such as driving and swimming under medical supervision 
Side Effects
- 
Sleepiness 
- 
Dizziness 
- 
Fatigue 
- 
Headache 
- 
Decreased appetite 
- 
Behavioral changes or aggressive behavior 
- 
Nausea and tremors 
 Most side effects are temporary and often reduce as your body adjusts. Contact your doctor if they persist or worsen.
How to Use
- 
Take Levenue 250 Tablet exactly as prescribed by your doctor 
- 
Swallow the tablet whole; do not chew, crush, or break it 
- 
Can be taken with or without food, preferably at the same time each day 
- 
Continue taking it regularly even if you feel well 
How It Works
Levenue 250 Tablet works by attaching to SV2A sites on nerve cells, suppressing abnormal brain activity and preventing the spread of electrical signals that cause seizures.
Points to Avoid
- 
Do not stop taking the medication without consulting your doctor 
- 
Avoid alcohol as it can worsen side effects 
- 
Missing doses can trigger seizures; do not double doses to make up 
Safety Advice and Precautions
- 
Pregnancy: Safe if prescribed by your doctor 
- 
Breastfeeding: Likely safe; monitor baby for sleepiness or feeding issues 
- 
Driving: Avoid if feeling sleepy or dizzy 
- 
Kidney: Use with caution; dose adjustment may be needed 
- 
Liver: Probably safe; consult doctor if liver disease is severe 
This is optimized for e-commerce listings with clear headings and concise information.

 
            
 
		                  
 
				 
				 
				 
				 
				 
				 
				 
				
Reviews
There are no reviews yet.